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Abstract
Background: This study employed various monitoring methods to assess the impact of repeated rounds of mass drug
administration (MDA) on bancroftian filariasis in Papua New Guinea, which has the largest filariasis problem in the Pacific
region.
Methodology/Principal Findings: Residents of rural villages near Madang were studied prior to and one year after each of
three rounds of MDA with diethylcarbamazine plus albendazole administered per World Health Organization (WHO)
guidelines. The mean MDA compliance rate was 72.9%. Three rounds of MDA decreased microfilaremia rates (Mf, 1 ml night
blood by filter) from 18.6% pre-MDA to 1.3% after the third MDA (a 94% decrease). Mf clearance rates in infected persons
were 71%, 90.7%, and 98.1% after 1, 2, and 3 rounds of MDA. Rates of filarial antigenemia assessed by card test (a marker for
adult worm infection) decreased from 47.5% to 17.1% (a 64% decrease) after 3 rounds of MDA. The filarial antibody rate
(IgG4 antibodies to Bm14, an indicator of filarial infection status and/or exposure to mosquito-borne infective larvae)
decreased from 59.3% to 25.1% (a 54.6% decrease). Mf, antigen, and antibody rates decreased more rapidly in children ,11
years of age (by 100%, 84.2%, and 76.8%, respectively) relative to older individuals, perhaps reflecting their lighter infections
and shorter durations of exposure/infection prior to MDA. Incidence rates for microfilaremia, filarial antigenemia, and
antifilarial antibodies also decreased significantly after MDA. Filarial DNA rates in Anopheles punctulatus mosquitoes that had
recently taken a blood meal decreased from 15.1% to 1.0% (a 92.3% decrease).
Conclusions/Significance: MDA had dramatic effects on all filariasis parameters in the study area and also reduced
incidence rates. Follow-up studies will be needed to determine whether residual infection rates in residents of these villages
are sufficient to support sustained transmission by the An. punctulatus vector. Lymphatic filariasis elimination should be
feasible in Papua New Guinea if MDA can be effectively delivered to endemic populations.
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Introduction
Lymphatic filariasis (LF) is a deforming and disabling infectious
disease that causes elephantiasis and hydroceles. The infection
affects some 120 million people in an estimated 83 countries in
tropical and subtropical regions, with an estimated 1.2 billion
individuals at risk [1]. Most LF is caused by Wuchereria bancrofti,a
nematode parasite that is transmitted to humans by mosquitoes.
The World Health Assembly passed a resolution in 1997 that
called for global elimination of LF as a public health problem
(WHA Resolution 50.29, see www.filariasis.org). The World
Health Organization (WHO) developed a plan for elimination
that is based on selective diagnosis to identify endemic areas
followed by repeated, annual cycles of mass drug administration
(MDA) of antifilarial medications [1,2]. The most recent summary
from WHO reported that approximately 1.9 billion doses of MDA
were distributed to more than 500 million individuals between
2000 and 2007 [3]. Thus, the Global Programme to Eliminate
Lymphatic Filariasis (GPELF) is the largest infectious disease
intervention program attempted to date based on MDA. Applied
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methods for measuring the impact of MDA. Recent papers have
reported encouraging data on the impact of MDA with
diethylcarbamazine (DEC) plus albendazole on various filariasis
parameters in Egypt and emphasized the importance of
compliance in MDA programs [4,5]. However, more information
is needed from areas with different epidemiological and ecological
parameters, e.g. mosquito vectorial capacity, transmission inten-
sity, baseline infection rates, and climate.
Bancroftian filariasis is a major public health problem in Papua
New Guinea [6]. With approximately 39% of its population
infected, the country has some of the highest LF infection rates in
the world [7], despite the fact the principal vectors there (Anopheles
punctulatus group, which also transmit malaria) are less efficient for
filariasis transmission than Culex or Aedes mosquitoes that serve as
vectors in other endemic regions [6,8]. At this time, Papua New
Guinea has more filariasis cases than any other country in the
Pacific region [9]. Although it is the only country in the region that
has not yet fully implemented a national LF elimination program,
the Papua New Guinea Department of Health has recently
initiated a MDA program for elimination in several provinces. In
some areas, MDA will overlap with the distribution of insecticide-
treated bednets for malaria control. This overlap in public health
interventions may benefit LF elimination efforts, as suggested by
reports from the Solomon Islands where DDT spraying (used for
malaria control) reduced LF transmission [10].
Several studies conducted over the past 10 years have assessed
the impact of MDA on LF infection parameters in Papua New
Guinea. For example, a study performed in 14 villages in East
Sepik Province found that four rounds of MDA with DEC plus
ivermectin or with DEC alone (drug regimens that have been
superseded by the current WHO recommendation of single dose
DEC plus albendazole) dramatically decreased microfilaremia (Mf)
prevalence rates and transmission parameters in areas with high
and moderate baseline infection and transmission rates [11].
Other studies in offshore island communities in Papua New
Guinea found dramatic decreases in Mf and/or filarial antigen-
emia rates following MDA or community distribution of DEC
alone or DEC with albendazole [12,13]. We now report results
from a community study that was designed to evaluate the efficacy
of repeated rounds of MDA with DEC plus albendazole
(distributed according to WHO guidelines [14]) on a number of
filariasis infection parameters. Results of this study should be
useful for those responsible for planning and implementing
national LF elimination programs in Papua New Guinea and in
other areas where filariasis is transmitted by Anopheles mosquitoes.
Methods
Study site
The study was performed in 4 villages in the Usino-Bundi
district, Madang Province, Papua New Guinea. The villages are
located approximately 40 km southwest of the provincial capital,
Madang town. The study villages were located at least 2 km from
untreated filariasis-endemic villages. This is the estimated flight
range of the local mosquito vector [15]. Villages were mapped and
censuses were conducted prior to the first round of MDA and
annually thereafter. Two Infection prevalence surveys were
performed before the first round of MDA, and this was repeated
approximately 12 months after each of three annual rounds of
MDA.
Field procedures and MDA
Field teams comprised of trained nurses and field technicians
met with community leaders and held outdoor community
education sessions to inform people about the health significance
and biology of LF, the planned MDA program, and the
importance of blood tests for monitoring the impact of MDA.
Annual follow-up meetings were held to communicate preliminary
results and to provide community members with opportunities to
ask questions about the project.
Community liaison personnel mobilized village residents to
participate in the study. Children ,2 years of age, children who
weighed ,10 kg, pregnant women, and people with severe
chronic illness or acute illness with fever were excluded from the
study. We reassessed eligibility for treatment each year. For
example, women who were pregnant in year 1 were eligible for the
study in later years if they were not pregnant. Survey teams
enrolled subjects in the late afternoon by obtaining oral informed
consent from adults and recording demographic information.
Enrollment of children required their assent and consent from at
least one parent. The population was surveyed twice prior to the
first round of MDA. The first pre-MDA survey (pre-MDA-A,
which collected day blood samples for antigen and antibody
testing only without microfilaria testing) was performed approx-
imately 2 years prior to the first round of MDA. The second pre-
MDA survey (pre-MDA-B, with blood for Mf, antigen, and
antibody testing) was performed together with the first round of
MDA (with blood collection just prior to treatment).
MDA comprised the WHO-recommended regimen of a single
oral dose of diethylcarbamazine citrate (6 mg/kg body weight)
with albendazole (400 mg regardless of weight). This was repeated
once per year for a total of three years. Project staff directly
observed ingestion of antifilarial medications. Some people agreed
to receive MDA but refused to provide blood samples. MDA
compliance rates were estimated by dividing the number of people
who ingested DEC with albendazole by the number of village
residents in the census who were at least 2 years of age. This is
similar to ‘‘observed coverage’’ in GPELF guidelines [14].
However, persons ineligible for treatment (e.g., pregnant women)
are included in the denominator for our compliance calculations
but not in the GPELF ‘‘observed coverage’’.
Author Summary
Lymphatic filariasis (LF) is a deforming and disabling
disease that is caused by parasitic worms that are
transmitted by mosquitoes. While a number of countries
have initiated LF elimination programs based on mass
drug administration (MDA), relatively little good informa-
tion is available on the impact of MDA on filariasis
prevalence and incidence rates in populations. This study
assessed the impact of three rounds of MDA (with single
doses of diethylcarbamazine and albendazole) on filariasis
infection rates in villages in Papua New Guinea, which has
the largest filariasis problem in the Pacific region. MDA
dramatically reduced rates for all filariasis infection markers
tested. These included microfilaremia (parasites in blood
that are necessary for transmission of the infection), filarial
antigenemia (a marker for adult worm infection), anti-
filarial antibodies (which indicate infection or heavy
exposure to the parasite), and parasites in mosquitoes
that transmit the infection. In addition to curing existing
infections, MDA also reduced new infection rates in the
study population to very low levels. These results suggest
that it should be possible to eliminate LF in Papua New
Guinea if MDA can be effectively delivered to endemic
populations.
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All tests were performed in the Papua New Guinea Institute of
Medical Research Laboratories near Madang. Microfilaremia was
assessed by membrane filtration of 1 ml of venous blood collected
between 9 p.m. and 12 midnight [16]. The Mf prevalence rate was
calculated by dividing the number of people who were Mf positive
by the number of people tested for Mf. Few blood samples were
collected from children younger than 6 years of age, and results
from these samples are not included in this report. We also
calculated community microfilaria load (CMFL) as a measure of
the total amount of Mf present in study communities as previously
described [17]. CMFL is defined as the antilog of the [sum of log
(X+1)/N]–1, where X is the MF count in positive subjects and N is
the number of people tested for microfilaremia.
Circulating filarial antigenemia (CFA) was assessed with a rapid-
format antigen card test (Filariasis Now, Binax Inc., Portland,
Maine, USA) [18,19]. Test instructions call for testing 100 mlo f
whole blood. We tested 70 ml of plasma, which is the approximate
volume of plasma in 100 ml of whole blood. Card tests were read
visually at 10 minutes. IgG4 antibodies to recombinant filarial
antigen Bm14 in human plasma were detected by ELISA as
previously described [20]. Sera were tested in duplicate, and
borderline samples were retested. Prior studies have shown that
this test is sensitive and specific for infection or heavy exposure to
filarial parasites [20–22].
Molecular xenomonitoring
Mosquitoes were collected with CDC light traps (without dry
ice) placed in houses (1 night per house) in study villages over 4
months period before MDA commenced and for 4 months starting
6 to 9 months following each round of MDA. Two pre-MDA
mosquito collections were conducted. The first (pre-MDA-A) was
conducted approximately 12 to 18 months prior to the first round
of MDA; the second (pre-MDA-B) was 1 to 5 months prior to the
first round of MDA.
Blood-engorged, gravid, or semi-gravid An. punctulatus group
mosquitoes (all of which had recently ingested blood) were
identified by morphology and sorted into pools by household.
W. bancrofti DNA was detected in mosquito pools by PCR as
previously described in detail [23–25], except mosquitoes were
macerated by vortexing with ball bearings [26] instead of by
mortar and pestle. Mosquito infection rates (maximum likelihood
estimates with 95% confidence intervals) were calculated with
PoolScreen 2.02 software [27].
Data entry and statistical methods
Data entry was performed with Visual FoxPro software with field
limits and double data entry. We used the SPSS v.14 software
package (SPSS, Chicago, IL) for statistical analysis. The chi-square
test was used to assess the significance of differences in proportions.
Ethical clearance
This study (including the oral consent process) was reviewed and
approved by institutional review boards at Washington University
School of Medicine and Case Western Reserve University and the
Medical Research Advisory Committee of the Papua New Guinea
Department of Health. The sponsor of the study (Division of
Microbiology and Infectious Diseases, NIAID, NIH, Bethesda,
MD) also reviewed the study protocol to ensure compliance with
GCP standards. Study personnel informed prospective study
participants about the study by reading them a consent document
in the local language. Oral consent was documented on case report
forms. Participation by children required consent from at least one
parent and the child’s assent. As noted above, some subjects agreed
to take anti-filarial medications but refused blood tests.
Results
Pre-MDA human infection parameters
Table 1 shows baseline infection indicators by age group just
prior to the first round of MDA (pre-MDA-B survey data). Mf
prevalence increased dramatically up to age 20 years, with slightly
higher rates in older age groups. The mean6SD of the number of
Mf per ml in 106 microfilaremic subjects was 61061073 (median
161; range 1–5,960). CFA and Bm14-specific IgG4 antibody rates
increased dramatically from age 6–10 years to 21–30 years, with
slight increases (CFA) or little change (Bm14) in older age groups.
Antibody and CFA rates were much higher than Mf rates in all
age groups. Persons with Mf or filarial antigenemia had a
significantly higher antibody rate (81.9%, n=279) than persons
with negative Mf and CFA tests (37.6%, N=287) (P,0.001).
Antibody rates were higher than CFA rates in younger age groups
(#30 years of age, P,0.001), but CFA rates were similar to
antibody rates in older people (difference not significant). Filarial
infection rates (Mf and CFA) were significantly higher in males
than in females (Table 2). Males also had higher antifilarial
antibody rates, but the difference was not statistically significant.
Gender differences in infection and antibody rates were much
more striking in adults than in children 6 to 15 years of age,
although the same trends were present in children.
Effects of MDA on filariasis infection parameters in
humans
The mean MDA compliance rate over the 3 rounds of MDA was
72.9% (Table 3). However, compliance rates were much lower in
children 2–5 years of age compared to those in older individuals.
MDA had dramatic effects on all filariasis parameters examined
(Table 4). Over the three annual rounds of MDA, microfilaremia
(Mf prevalence rates and CMFL) decreased more rapidly and to
lower levels than CFA or antibody rates. Antigenemia and
antibody prevalence rates in young children decreased more after
MDA than rates for the total study population.
Seven of 529 subjects tested had Mf one year after the third
round of MDA. Mf counts in these subjects ranged from 1–52 Mf/
ml (mean 18.0620.5; median 9). These subjects tended to have
Table 1. Filariasis infection parameters by age in Usino
villages just prior to the first round of mass drug
administration.
Age Range Mf (%) CFA (%) Bm14 (%)
6–10 3/125 (2.4) 22/120 (18.3) 43/120 (35.8)
11–15 7/90 (7.8) 25/87 (28.7) 40/87 (46.0)
16–20 13/60 (21.7) 27/60 (45) 37/60 (61.7)
21–30 31/131 (24.4) 78/128 (60.9) 95/129 (73.6)
31–40 24/80 (30.0) 52/79 (65.8) 54/79 (68.4)
41–50 24/49 (29.2) 34/47 (72.3) 37/48 (77.1)
51+ 13/37 (35.1) 27/37 (73.0) 26/37 (70.3)
Total 106/571 (18.6) 265/558 (47.5) 332/560 (59.3)
Abbreviations: Mf, microfilaremia; CFA, circulating filarial antigenemia; Bm14,
antibodies to recombinant filarial antigen Bm14.
Data shown are the number of positive tests and the total number of tests
performed (% positive).
doi:10.1371/journal.pntd.0000344.t001
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detected after MDA round 3 had not received MDA; two had
been treated once, one had been treated twice, and two had been
treated three times.
Sensitivity of the CFA and Bm14 antibody tests in Mf-
positive subjects before and after MDA
Table 5 shows CFA and antibody rates in Mf-positive subjects
detected in study villages before MDA and after each round of
MDA. These rates did not change significantly after MDA. P
values for differences in CFA and Bm14 antibody rates (for
samples from Mf-positive subjects) in different years of the study
were 0.60 and 0.78, respectively (chi-square).
Longitudinal observations on microfilaremia after MDA
Longitudinal Mf data were available for 104 subjects who were
initially Mf positive and who had repeat Mf testing approximately
one year after one or more rounds of MDA until Mf clearance was
achieved. Mf clearance rates were 76% (79/107), 95.2% (99/104),
and 98.1% (102/104) after 1, 2, or 3 rounds of treatment,
respectively; 2 subjects had persistent microfilaremia after 3 rounds
of treatment. Subjects with higher baseline Mf counts tended to
require more rounds of MDA to completely clear Mf. The
geometric mean and median Mf counts for 79 people who cleared
Mf after one round of MDA were 64.8 and 89 (range, 1–3813);
geometric mean and median Mf counts for 25 subjects who failed to
clear Mf after one round of MDA were 604 and 833 (range 11–
5279). The difference in baseline Mf counts between the two groups
was statistically significant (P,0.001 by the Mann Whitney U test).
Microfilaria incidence rates in persons who were Mf-negative
just prior to MDA were 1.7% (7/408), 0.4% (2/555), and 0.2%
(1/472) after MDA rounds 1, 2, and 3, respectively. Note that Mf
incidence data were not available for the period between the two
pre-MDA surveys. Despite this, the decrease in Mf incidence rates
after MDA was statistically significant (P=0.013 by chi square).
The mean Mf count in persons with Mf incidence was 86.26112
Mf/ml (median 26, range 7–353). Of course, some of these cases
may represent ‘‘pseudo-incidence’’ due to technical problems with
Mf detection or clerical errors. Most people with Mf incidence had
positive antigen (7/10) and antibody (8/10) tests one year prior to
the appearance of Mf. Four subjects with microfilaremia at
baseline were Mf-negative after MDA but positive again with
counts ranging from 47 to 68 Mf/ml one year later. Such cases of
temporary Mf clearance following treatment were not counted in
clearance or incidence results shown above.
Decreased antibody and antigenemia incidence rates
after MDA
Table 6 shows Bm14 antibody and CFA incidence events and
rates for the total study population and for children 6–15 years of
age. Incidence rates for the 2 year period between the 2 pre-MDA
surveys were high. Pre-MDA incidence rates in children ,16
years of age were not significantly different from those in older
people. Incidence rates decreased dramatically after MDA.
Incidence rates for the 2 year period after the first round of
MDA were significantly lower than those for the two year period
between the pre-MDA-A and pre-MDA-B surveys (Table 6).
Incidence rates for antifilarial antibodies and CFA decreased by
75% and 63% in the total study population (and by 68% and 70%
in children), respectively, after 3 rounds of MDA.
Effect of MDA on filarial DNA rates in mosquitoes
573 pools of recently fed (blood fed, gravid, or semigravid)
mosquitoes (3,729 mosquitoes) were tested for filarial DNA by PCR
(Table 7). The mosquitoes were collected from 114.6616.9 houses
per year (approximately 70% of the houses in study villages). The
mean number of recently fed mosquitoes per pool was 6.566.6
(median 4.0; range 1–28). The high baseline rate of filarial DNA in
mosquitoes just prior to MDA (15.1% in the pre-MDA-B survey)
decreased rapidly after MDA (Table 7). The 92.3 % decrease in the
filarial DNA rate after 3 rounds of MDA was similar to the 93%
decrease in the Mf prevalence rate observed in the human
population.
Discussion
This is the first detailed report on the effects of repeated rounds
of MDA with DEC and albendazole on filariasis infection
Table 2. Filariasis infection parameters by gender in Usino
villages just prior to the first round of mass drug
administration.
Gender Mf Prev (%) CFA Prev (%) Bm14 (%)
Females 6–15 2/89 (2.2) 15/87 (17.2) 33/87 (37.9)
Males 6–15 8/126 (6.3) 32/120 (26.7) 50/120 (41.7)
P value 0.28 0.15 0.69
Females .15 32/182 (17.6) 99/181 (54.7) 117/181 (64.6)
Males .15 64/174 (36.8) 119/170 (70) 132/172 (76.7)
P value ,0.001 0.005 0.02
All Females .5 34/271 (12.5) 114/268 (42.5) 150/268 (56.0)
All Males .5 72/300 (24.0) 151/290 (52.1) 182/292 (62.3)
P value 0.001 0.024 0.126
Abbreviations: Mf, microfilaremia; CFA, circulating filarial antigenemia; Bm14,
antibodies to recombinant filarial antigen Bm14.
Data shown are the number of positive tests and the total number of tests
performed (% positive). Numbers in the first column refer to age in years.
doi:10.1371/journal.pntd.0000344.t002
Table 3. Mass drug administration (MDA) compliance rates in Usino, Papua New Guinea.
Age
(yr) Round 1 Round 2 Round 3
Census MDA Compliance % Census MDA Compliance % Census MDA Compliance %
2–5 147 29.9 146 39 130 23.1
.5 825 75.3 854 82.8 841 81.7
$2 972 68.4 1000 76.4 971 73.9
doi:10.1371/journal.pntd.0000344.t003
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had baseline filarial infection rates that were high in the global
context but moderate for Papua New Guinea. Baseline infection
rates were higher in older age groups and higher in males than in
females. These trends probably reflect increased cumulative
exposure in older people and differences in exposure between
males and females. Since the gender differences were much more
striking in adults, these could also be related to biological factors
such as hormone levels.
The performance of the ICT antigen test and the Bm14
antibody test require some comment before we address the impact
of MDA on filariasis parameters in this study. The ICT test
detected filarial antigenemia in a high percentage of untreated Mf-
positive subjects (detected by membrane filtration of 1 ml of
venous blood), and this sensitivity was maintained after MDA.
This is in contrast to a recent study from Kenya that reported
decreased sensitivity of the ICT test in Mf carriers (detected by the
counting chamber method with 0.1 ml of finger prick blood) after
2 rounds of MDA [28]. The Bm14 antibody test was less sensitive
than the CFA test in Mf-positive subjects in the present study, and
it was also somewhat less sensitive than previously reported
[20,22]. However, both the CFA test and the Bm14 antibody test
were much more sensitive than Mf detection for detecting filariasis
activity in the study communities, and this is consistent with prior
reports [5,29]. Antibody rates in children ,11 years of age were
much higher than Mf or CFA rates, both before and after MDA.
This supports the strategy of testing sentinel populations of young
Table 5. Filarial antigenemia and Bm14 antibody rates in
subjects with microfilaremia before and after mass drug
administration (MDA).
CFA (%) Bm14 (%)
Pre-MDA-B 98/104 (94.2) 80/104 (76.9)
MDA-1 56/58 (96.6) 41/58 (70.7)
MDA-2 21/23 (91.3) 18/23 (78.3)
MDA-3 6/7 (85.7) 6/7 (85.7)
Data shown are the number of subjects with positive tests and the number of
Mf-positive subjects tested (% positive) before the first round of MDA and
approximately 12 months after each round of MDA.
Abbreviations: Mf, microfilaremia; CFA, circulating filarial antigenemia; Bm14,
IgG4 antibodies to recombinant filarial antigen Bm14.
doi:10.1371/journal.pntd.0000344.t005
Table 6. Incidence events and incidence rates for anti-filarial
antibodies and filarial antigenemia before and after mass drug
administration (MDA).
Survey
Bm14 Incidence
(rate, %)
CFA Incidence
(rate, %)
All ages
Pre-MDA-B 21/154 (6.8) 11/120 (4.6)
MDA-1 5/164 (3.0) 2/201 (1.0)
MDA-2 7/213 (3.3) 3/287 (1.0)
MDA-3 3/181 (1.7) 5/291 (1.7)
Age ,16
Pre-MDA-B 14/83 (8.4) 7/56 (6.3)
MDA-1 4/98 (4.1) 1/118 (0.8)
MDA-2 4/131 (3.1) 0/143 (0)
MDA-3 3 /111 (2.7) 3/155 (1.9)
Incidence events for each test were defined as positive tests in people who had
tested negative in the prior survey and who had never had a positive test in
prior years. This analysis is restricted to persons with data available for
consecutive years. The pre-MDA-B incidence data are for a 2 year interval (with
annual incidence rates shown in parentheses). Other incidence data are for one
year intervals. Annual incidence rates for the 2 year period between pre-MDA-A
and pre-MDA-B were significantly higher than rates for the two years following
the first round of MDA (P,0.001 by chi-square for all comparisons).
Abbreviations: CFA, circulating filarial antigenemia; Bm14, IgG4 antibodies to
recombinant filarial antigen Bm14.
doi:10.1371/journal.pntd.0000344.t006
Table 4. Filariasis parameters before and after mass drug administration (MDA) in Usino villages.
Mf (%) CMFL CFA (%) Bm14 (%)
All ages Pre-MDA-A n/a n/a 334/627 (53.3) 411/683 (60.2)
Pre-MDA-B 106/757 (18.6) 1.45 265/558 (47.5) 332/560 (59.3)
MDA-1 58/696 (8.3) 0.44 243 692 (35.1) 276/696 (39.7)
MDA-2 24/714 (3.4) 0.16 175/695 (25.2) 337/693 (48.8)
MDA-3 7/529 (1.3) 0.03 93/543 (17.1) 138/550 (25.1)
% Decrease 93.0 97.9 64.0 54.6
Age ,11 Pre-MDA-A n/a n/a 26/130 (20.0) 52/137 (38.0)
Pre-MDA-B 3/125 (2.4) 22/120 (18.3) 43/120 (35.8)
MDA-1 1/138 (0.7) 14/137 (10.1) 17/138 (12.3)
MDA-2 0/129 (0) 3/124 (2.4) 21/124 (16.3)
MDA-3 0/129 (0) 3/105 (2.9) 9/109 (8.3)
% Decrease 100 84.2 76.8
Data shown are the number of positive tests and the total number of tests performed (% positive).
The pre-MDA-A survey did not include Mf testing. CMFL was calculated for all ages only.
Pre-MDA-B values were used as the baseline for calculating % decrease for rates after MDA.
Abbreviations: Mf, microfilaremia; CMFL, community microfilarial load (see Methods); CFA, circulating filarial antigenemia; Bm14, antibodies to recombinant filarial
antigen Bm14.
doi:10.1371/journal.pntd.0000344.t004
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filariasis activity in communities [30].
Population MDA compliance rates were very good throughout
the 3-year study period. However, this required a lot of effort, with
multiple visits to the study villages and labor-intensive recruitment
of village residents. It might be easier to achieve high compliance
ratesina nationalMDAprogramthat wasnotlinkedtocollectionof
venous blood. MDA compliance rates were low in children ,6
years of age. This may have reflected parents’ concerns about blood
tests in their young children. We believe that the national LF
elimination program in Papua New Guinea will need to develop
new strategies to achieve high MDA compliance in young children.
Informationcampaigns should emphasize the dual benefits of MDA
on LF and soil-transmitted helminth infections.
MDA dramatically reduced all filariasis infection parameters in the
study villages. As in earlier studies, Mf rates in people and parasite
DNA rates in mosquitoes fell more rapidly than CFA or antibody
rates [5,31,32]. While low residual filarial DNA rates in mosquitoes
indicate the presence of Mf carriers in communities following MDA,
this does not necessarily mean that significant LF transmission will
continue in these areas. PCR can detect DNA from dead filarial
parasites in mosquitoes [33], and most Mf taken up by anopheline
vectors do not survive to become infective larvae (L3) [34,35].
CFA and anti-filarial antibody rates fell more rapidly after
MDA in children ,11 years of age than in the total study
population; this may be because infection intensities and years of
infection/exposure tend to be lower in young children than in
older individuals. Although infection rates decreased in children
after MDA, many young children had positive CFA and/or anti-
filarial antibody tests after 3 rounds of MDA. Of course, these
children had been exposed to the parasite for years prior to MDA.
Children born after LF transmission has been interrupted should
not have positive CFA or antibody tests [30]. Surveillance
activities to verify interruption of transmission should focus on
testing young children. Mosquito monitoring provides a non-
invasive means of detecting residual infections in communities if
the number of young children available for testing is small.
This study provided interesting longitudinal data on effects of
MDA on Mf clearance in individuals and on incidence rates for
different filariasis parameters. Mf clearance rates in this study after
one or more annual doses of DEC with albendazole were higher
than those reported from clinical trials performed in Sri Lanka and
Egypt [36–38]. However, while all subjects in the clinical trials had
high baseline Mf counts, all Mf carriers were considered in current
community-based study. The current study also found that Mf
clearance rates after MDA were lower in persons with high
baseline Mf counts. The incidence data are very exciting, because
they demonstrated that MDA significantly decreased the incidence
of Mf, CFA, and antifilarial antibodies in the study population.
This is the first study that has documented decreased filariasis
incidence rates following MDA. However, incidence events
observed after MDA-3 suggest that 3 rounds of MDA was not
sufficient to completely eliminate LF transmission in this setting.
The impact of three rounds of MDA in the current study was at
least as impressive as that recently reported from Egypt (Giza
governorate) with the same MDA regimen, although this ‘‘high
prevalence’’ study area in Egypt had lower LF infection rates before
MDA (11.5% Mf, 19.0% CFA, and 3.07% mosquito DNA) and
higher MDA compliance rates than our study site in Papua New
Guinea [5]. This suggests that the encouraging results reported from
Egypt can be replicated in areas with very different epidemiological
parameters. Changes in infection parameters following MDA must
be considered in the context of the local mosquito vector. An.
punctulatus is a less efficient LF vector than Cx. pipiens (the principal LF
vector species in Egypt). We do not know the minimum requirements
for sustained transmission of W. bancrofti by An. punctulatus. However,
Tisch et al recently reported that LF parameters continued to
decrease in villages in a different area of Papua New Guinea (in East
Sepik Province, approximately 300 km from the Usino study site) for
at least 5 years after Mf rates had been reduced to low levels by 5
rounds of MDA with DEC and ivermectin [32]. It is possible that
three rounds of DEC with albendazole (which reduced the Mf rate to
1.3% with a 97.9% decline in CMFL) would have been sufficient to
reduce LF transmission rates to unsustainable levels in the Usino
study area. The study villages received a fourth round of MDA in
2006; long term follow-up studies will be needed to determine
whether four rounds of MDA have interrupted LF transmission in
this area. For the time being, the results from Usino are quite
encouraging. Taken together with earlier studies, they suggestthat LF
elimination should be feasible in Papua New Guinea and other
endemic areas with Anopheles transmission if MDA can be effectively
delivered to endemic populations. Prospects for LF elimination
should be even brighter if MDA can be integrated with distribution of
insecticide-treated bednets [11].
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Table 7. Mosquito collections and filarial DNA rates in mosquitoes before and after mass drug administration (MDA).
Survey No. Pools Mosq. per Pool (SD) No. Mosquitoes Tested Filarial DNA Rate (95% CI)
Pre-MDA-A 97 6.8 (6.1) 565 11.4 (10.87–21.25
Pre-MDA-B 119 7.5 (7.3) 892 15.1 (11.7–19.2)
MDA-1 118 6.2 (6.4) 726 3.7 (2.2–5.6)
MDA-2 130 6.7 (6.8) 926 4.8 (3.3–6.7)
MDA-3 100 6.2 (6.4) 620 1.02 (0.4–2.2)
Totals 573 6.5 (6.6) 3,729
Filarial DNA was detected in mosquitoes by PCR, and rates (maximum likelihood with 95% CI) were estimated by PoolScreen. The filarial DNA rate in mosquitoes
collected in the MDA-3 survey (6 to 9 months after the third round of MDA) represented a 92.3% decrease from the rate in mosquitoes collected during the pre-MDA-B
survey (just prior to the first round of MDA).
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